Samsung Biologics signs $325M manufacturing pact with Celltrion

Samsung Biologics finalized a $325 million multi-year manufacturing agreement with Celltrion to produce key biologics. The contract leverages Samsung Biologics' CDMO capabilities to support Celltrion's biosimilar portfolio.

“Samsung Biologics secures a significant $325 million manufacturing contract with Celltrion, bolstering biosimilar production and global supply chains.”inforcapital.com

• 1 source
• inforcapital.comSamsung Biologics, Celltrion Forge $325M Manufacturing PactAlvaro de la MazaNov 7, 2026

Summarized from public sources; check the original articles before acting on it.